Translation proceeds in four phases: initiation, elongation, termination, and recycling.
Initiation Initiation involves the small subunit of the ribosome binding to the 5' end of mRNA with the help of
initiation factors. The ribosome and its associated factors assemble and bind to an mRNA. The first tRNA is attached at the
start codon. This process is defined as either cap-dependent, in which the ribosome binds initially at the 5' cap and then travels to the stop codon, or as cap-independent, where the ribosome does not initially bind the 5' cap. The 5' cap is added when the nascent pre-mRNA is about 20 nucleotides long.
Cap-dependent initiation Initiation of translation usually involves the interaction of certain key proteins, the
initiation factors, with a special tag bound to the 5'-end of an mRNA molecule, the
5' cap, as well as with the
5' UTR. These proteins bind the small (40S)
ribosomal subunit and hold the mRNA in place.
eIF3 is associated with the 40S ribosomal subunit and plays a role in keeping the large (60S) ribosomal subunit from prematurely binding. eIF3 also interacts with the
eIF4F complex, which consists of three other initiation factors:
eIF4A,
eIF4E, and
eIF4G.
eIF4G is a scaffolding protein that directly associates with both eIF3 and the other two components.
eIF4E is the cap-binding protein. Binding of the cap by eIF4E is often considered the rate-limiting step of cap-dependent initiation, and the concentration of eIF4E is a regulatory nexus of translational control. Certain viruses cleave a portion of eIF4G that binds eIF4E, thus preventing cap-dependent translation to hijack the host machinery in favor of the viral (cap-independent) messages.
eIF4A is an ATP-dependent RNA helicase that aids the ribosome by resolving certain secondary structures formed along the mRNA transcript. Recent structural biology results also indicated that a second eIF4A protein can simultaneously associate with the initiation complex, specifically interacting with eIF3. The
poly(A)-binding protein (PABP) also associates with the
eIF4F complex via eIF4G, and binds the
poly-A tail of most eukaryotic mRNA molecules. This protein has been implicated in playing a role in circularization of the mRNA during translation. This
43S preinitiation complex (43S PIC) accompanied by the protein factors moves along the mRNA chain toward its 3'-end, in a process known as 'scanning', to reach the
start codon (typically AUG). In
eukaryotes and
archaea, the
amino acid encoded by the start codon is
methionine. The Met-charged initiator tRNA (Met-tRNAiMet) is brought to the P-site of the small ribosomal subunit by
eukaryotic initiation factor 2 (eIF2). It hydrolyzes GTP, and signals for the dissociation of several factors from the small ribosomal subunit, eventually leading to the association of the large subunit (or the
60S subunit). The complete ribosome (
80S) then commences translation elongation. Regulation of protein synthesis is partly influenced by phosphorylation of
eIF2 (via the α subunit), which is a part of the eIF2-GTP-Met-tRNAiMet ternary complex (eIF2-TC). When large numbers of eIF2 are phosphorylated, protein synthesis is inhibited. This occurs under amino acid starvation or after viral infection. However, a small fraction of this initiation factor is naturally phosphorylated. Another regulator is
4EBP, which binds to the initiation factor
eIF4E and inhibits its interactions with
eIF4G, thus preventing cap-dependent initiation. To oppose the effects of 4EBP, growth factors phosphorylate 4EBP, reducing its affinity for eIF4E and permitting protein synthesis. While protein synthesis is globally regulated by modulating the expression of key initiation factors as well as the number of ribosomes, individual mRNAs can have different translation rates due to the presence of regulatory sequence elements. This has been shown to be important in a variety of settings including yeast meiosis and ethylene response in plants. In addition, recent work in yeast and humans suggest that evolutionary divergence in cis-regulatory sequences can impact translation regulation. Additionally, RNA
helicases such as
DHX29 and
Ded1/DDX3 participate in the process of translation initiation, especially for mRNAs with structured 5'UTRs.
Cap-independent initiation The best-studied example of cap-independent translation initiation in eukaryotes uses the
internal ribosome entry site (IRES). Unlike cap-dependent translation, cap-independent translation does not require a 5' cap to initiate scanning from the 5' end of the mRNA until the start codon. The ribosome can localize to the start site by direct binding, initiation factors, and/or ITAFs (IRES trans-acting factors) bypassing the need to scan the entire
5' UTR. This method of translation is important in conditions that require the translation of specific mRNAs during cellular stress, when overall translation is reduced. Examples include factors responding to apoptosis and stress-induced responses.
Elongation Elongation depends on
elongation factors. At the end of the initiation step, the mRNA is positioned so that the next codon can be translated during the elongation stage of protein synthesis. The initiator tRNA occupies the P site in the ribosome, and the A site is ready to receive an aminoacyl-tRNA. During chain elongation, each additional amino acid is added to the nascent polypeptide chain in a three-step microcycle. The steps in this microcycle are (1) positioning the correct aminoacyl-tRNA in the A site of the ribosome, which is brought into that site by eEF1, (2) forming the peptide bond, and (3) shifting the mRNA by one codon relative to the ribosome with the help of eEF2. Unlike bacteria, in which translation initiation occurs as soon as the 5' end of an mRNA is synthesized, in eukaryotes, such tight coupling between transcription and translation is not possible because transcription and translation are carried out in separate compartments of the cell (the
nucleus and
cytoplasm). Eukaryotic mRNA precursors must be processed in the nucleus (e.g., capping,
polyadenylation, splicing) in ribosomes before they are exported to the
cytoplasm for translation. Translation can also be affected by
ribosomal pausing, which can trigger endonucleolytic attack of the tRNA, a process termed mRNA no-go decay. Ribosomal pausing also aids co-translational folding of the nascent polypeptide on the ribosome, and delays protein translation while it is encoding tRNA. This can trigger ribosomal frameshifting. The last tRNA validated by the small ribosomal subunit (
accommodation) transfers the amino acid. It carries to the
large ribosomal subunit which binds it to one of the preceding admitted tRNA (
transpeptidation). The ribosome then moves to the next mRNA codon to continue the process (
translocation), creating an amino acid chain. In
bacterial translation, and
archaeal translation, translation occurs in the cytosol, where the ribosome binds to the mRNA. In
eukaryotes, translation can occur in the
cytoplasm and also across the membrane of the
endoplasmic reticulum through a process called
co-translational translocation. In co-translational translocation, the entire ribosome–mRNA complex binds to the outer membrane of the
rough endoplasmic reticulum (ER), and the new protein is synthesized and released into the ER; the newly created polypeptide can be immediately
secreted or stored inside the ER for future
vesicle transport and secretion outside the cell. Many types of
transcribed RNA, such as tRNA, ribosomal RNA, and small nuclear RNA, do not undergo a translation into proteins. Several
antibiotics act by inhibiting translation. These include
anisomycin,
cycloheximide,
chloramphenicol,
tetracycline,
streptomycin,
erythromycin, and
puromycin.
Prokaryotic ribosomes have a different structure from that of eukaryotic ribosomes, and thus antibiotics can specifically target bacterial
infections without harming a eukaryotic
host's cells.
Termination s, the ribosome,
transfer RNA, and
amino acids Termination of elongation depends on the
release factor eRF1 that recognizes all three stop codons. When a stop codon is reached, termination of the polypeptide occurs the ribosome is disassembled and the completed polypeptide is released.
eRF3 is a ribosome-dependent GTPase that helps eRF1 release the completed polypeptide. The human genome encodes a few genes whose mRNA stop codons are surprisingly leaky: In these genes, termination of translation is inefficient due to special RNA bases in the vicinity of the stop codon. Leaky termination in these genes leads to
translational readthrough of up to 10% of the stop codons of these genes. Some of these genes encode functional
protein domains in their readthrough extension so that new protein
isoforms can arise. This process has been termed 'functional translational readthrough'. When the A site of the ribosome is occupied by a stop codon (UAA, UAG, or UGA) on the mRNA, creating the primary structure of a protein. tRNA usually cannot recognize or bind to stop codons. Instead, the stop codon induces the binding of a release factor protein (RF1 & RF2) that prompts the disassembly of the entire ribosome/mRNA complex by the hydrolysis of the polypeptide chain from the peptidyl transferase center Drugs or special sequence motifs on the mRNA can change the ribosomal structure so that near-cognate tRNAs are bound to the stop codon instead of the release factors. In such cases of 'translational readthrough', translation continues until the ribosome encounters the next stop codon.
Recycling When the synthesised protein is released the complex ribosome disassembles into its subunits for recycling. The rate of error in synthesizing proteins has been estimated to be between 1 in 105 and 1 in 103 misincorporated amino acids, depending on the experimental conditions. The rate of premature translation abandonment, instead, has been estimated to be of the order of magnitude of 10−4 events per translated codon.
Regulation Translation is one of the key energy consumers in cells, hence it is strictly regulated. Numerous mechanisms have evolved that control and regulate translation in
eukaryotes as well as
prokaryotes. Regulation of translation can impact the global rate of protein synthesis which is closely coupled to the metabolic and proliferative state of a cell. To study this process, scientists have used a wide variety of methods such as structural biology, analytical chemistry (mass-spectrometry based), imaging of reporter mRNA translation (in which the translation of a mRNA is linked to an output, such as luminescence or fluorescence), detecting it via radioactive amino acid incorporation, and next-generation sequencing based methods. Other methods such as
toeprinting assay can also be used to determine the location of ribosomes of a particular mRNA in vitro, and footprints of other proteins regulating translation. To delve deeper into this intricate process, scientists typically use a technique known as ribosome profiling. This method enables researchers to take a snapshot of the translatome, showing which parts of the mRNA are being translated into proteins by ribosomes at a given time. Ribosome profiling provides valuable insights into translation dynamics, revealing the complex interplay between gene sequence, mRNA structure, and translation regulation. Single-cell ribosome profiling has revealed that genetic differences and their subsequent expression as mRNAs can also impact translation rate in an RNA-specific manner. Single-cell ribosome profiling has the potential to shed light on the heterogeneous nature of cells, leading to a more nuanced understanding of how translation regulation can impact cell behavior, metabolic state, and responsiveness to various stimuli or conditions.
Amino acid substitution In some cells certain
amino acids can be depleted and thus affect translation efficiency. For instance, activated
T cells secrete
interferon-γ which triggers intracellular
tryptophan shortage by upregulating the
indoleamine 2,3-dioxygenase 1 (IDO1) enzyme. Despite
tryptophan depletion, in-frame protein synthesis continues across tryptophan
codons. This is achieved by incorporation of
phenylalanine instead of tryptophan. The resulting peptides are called W>F "substitutants". Such W>F substitutants are abundant in certain
cancer types and have been associated with increased IDO1 expression. Functionally, W>F substitutants can impair
protein activity. ==Clinical significance==